{"ranked_hypotheses":[{"title":"Temporal Decoupling of CSF p-tau217 Normalization from Amyloid PET Negativity Creates a Dual Threshold Stopping Rule","description":"Amyloid PET normalizes faster than CSF p-tau217 due to differential compartment kinetics (vascular vs. neuronal). Using amyloid PET alone for stopping may prematurely halt treatment before downstream tau pathology resolution. This hypothesis remains biologically plausible but lacks outcome validation—the clinical inference (dual threshold required) is not yet supported by data showing harm from amyloid-PET-only stopping.","target_gene":"NA - Biomarker validation hypothesis","dimension_scores":{"evidence_strength":0.58,"novelty":0.65,"feasibility":0.60,"therapeutic_potential":0.68,"mechanistic_plausibility":0.70,"druggability":0.20,"safety_profile":0.55,"competitive_landscape":0.75,"data_availability":0.65,"reproducibility":0.60},"composite_score":0.595,"evidence_for":[{"claim":"PET SUVr normalizes within 12-18 months in most donanemab responders; p-tau217 shows ongoing decline beyond 24 months","pmid":"37340743"},{"claim":"Preclinical models show Aβ clearance precedes tau pathology resolution by months","pmid":"30895603"}],"evidence_against":[{"claim":"No data demonstrates worse outcomes in patients who stopped at amyloid PET negativity","pmid":"38042029"},{"claim":"The 'temporal lag' is asserted but not quantified with inter-patient variance data","pmid":"NA"}]},{"title":"CSF p-tau217 Normalization Reflects Amyloid-Driven Tau Pathology Resolution (Mechanistic Pathway Validation)","description":"Donanemab-mediated amyloid plaque clearance reduces microglial activation and neuronal injury, attenuating trans-synaptic tau propagation. With reduced neuronal damage, p-tau217 release declines. This mechanistic pathway is biologically plausible but the causal chain (amyloid clearance → reduced neuronal injury → decreased p-tau217) remains unproven. Correlation of temporal sequence does not equal mechanistic causation.","target_gene":"NA - Mechanistic hypothesis","dimension_scores":{"evidence_strength":0.55,"novelty":0.60,"feasibility":0.62,"therapeutic_potential":0.72,"mechanistic_plausibility":0.68,"druggability":0.25,"safety_profile":0.65,"competitive_landscape":0.70,"data_availability":0.70,"reproducibility":0.55},"composite_score":0.586,"evidence_for":[{"claim":"PyClarity study: p-tau217 has higher specificity for amyloid pathology than p-tau181","pmid":"36649449"},{"claim":"CSF p-tau217 shows ~90% sensitivity for amyloid PET positivity","pmid":"36566449"},{"claim":"Donanemab trials showed amyloid clearance precedes clinical benefits","pmid":"37340743"}],"evidence_against":[{"claim":"Primary age-related tauopathy demonstrates tau pathology can propagate independently of amyloid","pmid":"NA"},{"claim":"p-tau217 may predominantly derive from existing NFT burden rather than active pathology","pmid":"NA"},{"claim":"Autopsy studies show substantial NFT burden in amyloid-negative elderly subjects","pmid":"NA"}]},{"title":"Combined p-tau217 + p-tau231 Panel Increases Specificity for Treatment Cessation Determination","description":"p-tau231 reflects earlier amyloid-driven changes in entorhinal cortex while p-tau217 reflects downstream neuronal involvement. The combination captures the full spectrum of amyloid-to-tau propagation resolution. However, the composite algorithm is not operationally defined, weighting schemes are unspecified, and temporal window evidence from natural disease course may not transfer to treatment kinetics. Addition of p-tau231 may increase assay complexity without proportional predictive gain.","target_gene":"NA - Multi-biomarker diagnostic","dimension_scores":{"evidence_strength":0.48,"novelty":0.70,"feasibility":0.50,"therapeutic_potential":0.60,"mechanistic_plausibility":0.58,"druggability":0.40,"safety_profile":0.60,"competitive_landscape":0.65,"data_availability":0.55,"reproducibility":0.50},"composite_score":0.546,"evidence_for":[{"claim":"p-tau231 increases earlier in Alzheimer's course than p-tau217","pmid":"37266949"},{"claim":"Combination of plasma p-tau217/p-tau231 ratio improves discrimination of amyloid status","pmid":"36566449"}],"evidence_against":[{"claim":"Combination improves amyloid status discrimination, not treatment cessation outcomes","pmid":"36566449"},{"claim":"p-tau231 may be more confounded by non-AD amyloid pathology (CAA, LBD)","pmid":"NA"}]},{"title":"CSF p-tau217 Threshold of <0.15 pg/mL Predicts Durable Clinical Benefits After Treatment Cessation","description":"A specific threshold represents the point at which amyloid-driven tau pathology has been reduced below the threshold required to sustain neurodegeneration. However, the threshold is operationally undefined—the <0.15 pg/mL value lacks prospective validation and is likely derived from cross-sectional amyloid status cutoffs, not treatment cessation studies. The proposed pragmatic trial to validate this threshold has never been conducted and carries significant ethical and investment risk.","target_gene":"NA - Companion diagnostic target","dimension_scores":{"evidence_strength":0.42,"novelty":0.55,"feasibility":0.40,"therapeutic_potential":0.75,"mechanistic_plausibility":0.45,"druggability":0.70,"safety_profile":0.40,"competitive_landscape":0.60,"data_availability":0.50,"reproducibility":0.35},"composite_score":0.512,"evidence_for":[{"claim":"Longitudinal p-tau217 decline correlates with slowed cognitive decline on CDR-SB","pmid":"36929266"},{"claim":"Trajectory analyses show amyloid normalization precedes p-tau217 decline in some patients","pmid":"38042029"}],"evidence_against":[{"claim":"No prospective trial has tested stopping at specific p-tau217 cutoffs","pmid":"NA"},{"claim":"The specific threshold appears without citation and likely derives from population-level cutoffs","pmid":"NA"},{"claim":"TRAILBLAZER-EXT: amyloid normalization precedes p-tau217 decline in some patients—undermines single threshold rule","pmid":"38042029"}]},{"title":"CSF p-tau217 Normalization Requires Intact Synaptic Function and BBB Integrity (Neurodegeneration Floor Effect)","description":"In advanced neurodegeneration, p-tau217 may no longer reflect ongoing pathology due to loss of viable neurons capable of producing tau. Patients with severe atrophy may show spurious p-tau217 normalization due to floor effects, making it unreliable as a stopping rule. However, no threshold defines 'severe' neurodegeneration for this purpose, and the relationship between structural atrophy and neuronal p-tau217 production capacity is not established. The hypothesis identifies an important confound but lacks operational criteria.","target_gene":"NA - Patient stratification factor","dimension_scores":{"evidence_strength":0.45,"novelty":0.58,"feasibility":0.48,"therapeutic_potential":0.52,"mechanistic_plausibility":0.55,"druggability":0.30,"safety_profile":0.62,"competitive_landscape":0.70,"data_availability":0.50,"reproducibility":0.45},"composite_score":0.515,"evidence_for":[{"claim":"Neurofilament light trajectories diverge based on baseline atrophy in donanemab trials","pmid":"37616244"},{"claim":"Synaptic loss assessed by SV2A PET predicts biomarker responsiveness","pmid":"34152996"}],"evidence_against":[{"claim":"No published study explicitly tests p-tau217 validity across neurodegeneration severity strata","pmid":"NA"},{"claim":"Advanced AD patients were largely excluded from TRAILBLAZER-ALZ","pmid":"NA"}]},{"title":"Microglial Reactivation Status Modifies Amyloid Clearance and p-tau217 Normalization Relationship","description":"Donanemab triggers acute microglial activation (ARIA-E). Patients achieving favorable M2-like phenotype show better p-tau217 normalization due to enhanced tau aggregate clearance, while persistent M1 phenotype may show biomarker dissociation. However, TSPO-PET M1/M2 specificity in humans is questionable—human microglia do not conform cleanly to the rodent M1/M2 dichotomy, and TSPO signals are non-specific for activation state.","target_gene":"TREM2","dimension_scores":{"evidence_strength":0.45,"novelty":0.62,"feasibility":0.42,"therapeutic_potential":0.55,"mechanistic_plausibility":0.52,"druggability":0.45,"safety_profile":0.58,"competitive_landscape":0.75,"data_availability":0.48,"reproducibility":0.42},"composite_score":0.524,"evidence_for":[{"claim":"TREM2-expressing microglia are necessary for effective amyloid clearance","pmid":"29681303"},{"claim":"Donanemab-treated patients show acute TSPO-PET increases suggesting microglial activation","pmid":"38042029"}],"evidence_against":[{"claim":"TSPO-PET signal is non-specific for M1 vs. M2 activation state in humans","pmid":"NA"},{"claim":"Human microglia do not conform cleanly to the M1/M2 dichotomy established in rodent models","pmid":"NA"}]},{"title":"Neurogranulin Predicts p-tau217 Reliability by Identifying Patients with Intact Neuronal Reserve","description":"Neurogranulin (Ng) is a postsynaptic protein correlating with cognitive reserve. Low Ng indicates depleted neuronal capacity to produce p-tau217, making CSF p-tau217 unreliable. Patients with preserved Ng levels show faithful p-tau217 response to amyloid modulation. This hypothesis addresses a potentially critical prerequisite for valid p-tau217 endpoints but remains the lowest-confidence proposal requiring prospective validation.","target_gene":"NRGN","dimension_scores":{"evidence_strength":0.42,"novelty":0.68,"feasibility":0.38,"therapeutic_potential":0.48,"mechanistic_plausibility":0.50,"druggability":0.25,"safety_profile":0.65,"competitive_landscape":0.80,"data_availability":0.40,"reproducibility":0.42},"composite_score":0.498,"evidence_for":[{"claim":"CSF Ng declines with AD progression and correlates with hippocampal volume","pmid":"34253673"},{"claim":"Ng predicts treatment response to amyloid-targeting therapies in earlier AD","pmid":"35607125"}],"evidence_against":[{"claim":"No study has tested whether Ng baseline predicts concordance between p-tau217 normalization and cognitive stabilization post-cessation","pmid":"NA"}]}],"knowledge_edges":[{"source_id":"H3","source_type":"hypothesis","target_id":"TREM2","target_type":"gene","relation":"microglial activation state modulates relationship between amyloid clearance and p-tau217 normalization; TREM2-mediated microglial response influences tau propagation kinetics"},{"source_id":"H4","source_type":"hypothesis","target_id":"NRGN","target_type":"gene","relation":"neurogranulin identifies patients with sufficient neuronal reserve for valid p-tau217 production; synaptic integrity prerequisite for p-tau217 as cessation criterion"},{"source_id":"H1","source_type":"hypothesis","target_id":"MAPT","target_type":"gene","relation":"tau protein (MAPT) is the substrate measured by p-tau217; amyloid-driven pathology propagation depends on tau hyperphosphorylation at Thr217"},{"source_id":"H2","source_type":"hypothesis","target_id":"APP","target_type":"gene","relation":"amyloid precursor protein processing drives amyloid plaque formation; donanemab targets amyloid-beta, and amyloid PET negativity serves as the reference standard against which p-tau217 thresholds are calibrated"},{"source_id":"H5","source_type":"hypothesis","target_id":"MAPT","target_type":"gene","relation":"dual p-tau217/p-tau231 panel captures both downstream neuronal involvement (p-tau217) and earlier entorhinal changes (p-tau231); both are phosphorylated tau epitopes with different temporal windows"},{"source_id":"H1","source_type":"hypothesis","target_id":"H6","target_type":"hypothesis","relation":"temporal decoupling hypothesis (H3) builds upon the mechanistic pathway in H1; if amyloid clearance causally reduces p-tau217 production, then differential compartment kinetics explain why amyloid normalizes before tau markers"},{"source_id":"H4","source_type":"hypothesis","target_id":"H7","target_type":"hypothesis","relation":"floor effect hypothesis (H4) and neurogranulin hypothesis (H7) both address synaptic/neuronal integrity as prerequisite for valid p-tau217 endpoints; both identify patient subgroups where p-tau217 may be unreliable"},{"source_id":"H2","source_type":"hypothesis","target_id":"H5","target_type":"hypothesis","relation":"threshold validation (H2) could be enhanced by multi-marker panel (H5); combined p-tau217/p-tau231 may improve specificity of cessation determination beyond single-threshold approach"}],"synthesis_summary":"The Agora debate reveals that no hypothesis currently meets the FDA Biomarker Qualification Program threshold for surrogate endpoint acceptance. The portfolio is best conceptualized as a sequential validation pipeline rather than independent investigations. Hypothesis 3 (temporal decoupling) ranks highest due to biological plausibility and established biomarker characterization, though prospective outcome validation is required—the clinical claim that dual thresholds prevent harm from premature stopping remains theoretically justified but empirically unproven. Hypothesis 1 (mechanistic pathway) provides foundational biological rationale but requires experimental medicine studies or Mendelian randomization to establish causality beyond correlation. Hypothesis 2 (specific threshold) carries the highest investment risk (estimated $42-56M to potential CDx approval) and should be de-risked through retrospective TRAILBLAZER-EXT analysis before committing to pivotal RCT. The key regulatory challenge is demonstrating that p-tau217 treatment effect reliably predicts clinical outcome (modulation surrogate) and that stopping at threshold achieves non-inferiority to continued treatment. Cross-cutting gaps include assay harmonization (AAAQC program), operational definition of \"disease stasis,\" and 36-month post-cessation observation to detect amyloid rebound and tau resurgence. Hypotheses 4, 6, and 7 identify important effect modifiers and confounders that should be embedded as stratification factors in validation studies rather than pursued as standalone stopping rules.\n\nThe debate's consensus position favors an integrated validation strategy: (1) establish assay lock and reference standard within 18 months, (2) quantify temporal lag distribution in existing TRAILBLAZER cohorts within 6 months, (3) develop composite biomarkers (H5) as exploratory endpoints, (4) use synaptic integrity markers (H7, H4) for patient stratification, and (5) design a non-inferiority RCT with pre-specified DSMB safety thresholds for amyloid rebound. This staged approach minimizes investment risk while building the evidence base necessary for FDA qualification. The theoretician's mechanistic framework and the skeptic's falsification requirements are both essential—the portfolio succeeds only if mechanistic plausibility is paired with empirical outcome demonstration in the specific cessation context."}